DA Lespezeanu¹*, G Laura², C Serafinceanu³, DF Ungureanu⁴ and C Constantin⁵

¹Professor. N. Paulescu" Institute of Diabetes, Outpatient Clinic, Bucharest, Romania
²Carol Davila" University Military Hospital, Diabetes Department, Bucharest, Romania
³Regina Maria" Hospital - Titu Maiorescu University, Surgery, Bucharest, Romania
⁴Prof Agrippa Ionescu" University Hospital, Diabetes Department, Bucharest, Romania
⁵Carol Davila" University Military Hospital, Diabetes Department, Bucharest, Romania

*Corresponding Author: DA Lespezeanu, Professor. N. Paulescu" Institute of Diabetes, Outpatient Clinic, Bucharest, Romania.

Received: May 23, 2025; Published: June 02, 2025

Abstract

Between August 2020 and November 2022, we assessed 40 women with breast cancer, type 2 diabetes, and COVID-19. Patients were treated with insulin Glargine U100 or U300, with or without Alpha Lipoic Acid, and antibiotics. Glargine U100 combined with Alpha Lipoic Acid led to faster glycemic control and normalization of inflammatory markers (IL-1, IL-6, CRP) compared to U300. These findings support early use of basal insulin and anti-inflammatory therapy to manage hyperglycemia and inflammation in high-risk diabetic patients during the COVID-19 pandemic.

Keywords: Therapies; Inflammatory Syndrome; Diabetes Mellitus

References

1. Yu B., et al. “Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes”. Cell Metabolism 33 (2021): 65-77.e2.
2. Gangadaran P., et al. “COVID-19 and Diabetes: What Do We Know so Far?” Experimental Biology and Medicine 247 (2022): 1330-1334.
3. George TP., et al. “Cytokines Involved in COVID-19 Patients with Diabetes: A Systematic Review”. Current Diabetes Reviews 19 (2022).
4. Chawla M., et al. “Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel”. Diabetes Therapy 12 (2021): 133-142.
5. Mcgurnaghan SJ., et al. “Cohort Profile: The Scottish Diabetes Research Network National Diabetes Cohort - A Population-Based Cohort of People with Diabetes in Scotland”. BMJ Open (2022): 12.
6. Bouhanick B., et al. “Diabetes and COVID-19”. Therapies 75 (2020): 327-333.
7. Peric S and Stulnig TM. “Diabetes and COVID-19: Disease-Management-People”. Wiener klinische Wochenschrift 132 (2020): 356-361.
8. Montazersaheb S., et al. “COVID-19 Infection: An Overview on Cytokine Storm and Related Interventions”. Virology Journal (2022): 19.

Citation

Citation: DA Lespezeanu., et al. “Unconventional Therapies in COVID Inflammatory Syndrome for Type 2 Diabetes Mellitus Patients".Acta Scientific Nutritional Health 9.7 (2025): 02-04.

Copyright

Copyright: © 2025 DA Lespezeanu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.